NCT06815172Active, not recruiting
PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.
PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos): Study of Risk Factors for Exocrine Pancreatic Neoplasms.
Source: ClinicalTrials.gov · Last updated 7 Feb 2025
Brief summary (registry, in English)
The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. The data collected will be used to generate specific hypotheses on the possible environmental and occupational determinants of the disease. The study aims to evaluate: 1. To evaluate the exposure to asbestos occurred during life, through the use of a standardized questionnaire to be administered to incident cases (newly diagnosed) of histologically diagnosed pancreatic adenocarcinoma afferent to the Medical Oncology Unit Prof. Ardizzoni in Group A, the exposure to asbestos occurred during the course of life; 2. To produce quantitative estimates of the risk of pancreatic adenocarcinoma associated with asbestos exposure. 2.3. To evaluate the presence of asbestos fibers directly on histological sections of pancreatic cancer of patients exposed to asbestos and undergoing surgery.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 10 Jan 2025
- Start date
- 28 May 2020
- Primary completion date
- Sept 2025
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Diseases
- Pancreatic cancer
- NCT number
- NCT06815172
What you commit to
- Study type: Observational
- Planned participants: 500
- From 28 May 2020 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients in danger of life or hospitalized waiting to undergo surgery for pathologies other than those of inclusion
Other illness
- Patients with a history of malignant neoplastic pathologies
- Patients suffering from diseases associated with exposure to asbestos: pleuropatias (parietal plaques, diffuse visceral thickening, recurrent effusions and round atelectasis) and pulmonary diseases (alveolitis and asbestosis)
Other
- 1\. Prevalent cases of the pathology under study
- Group B
- Patients with pancreatic adenocarcinoma
Who the study is looking for
- Incident cases (new diagnosis) of histologically diagnosed pancreatic adenocarcinoma afferent to the Medical Oncology Unit Prof. Ardizzoni
- Age 30-90 years
- Ability to complete the questionnaire
- Ability to read and understand Italian
- Signing the informed consent form
- Patients admitted to the S.Orsola-Malpighi Polyclinic in the ophthalmology, gynecology and urology departments with a diagnosis of cataracts, uterine fibroids and prostate adenoma previously included in the CARA study.
- Age 30-90 years
- Ability to complete the questionnaire
- Ability to read and understand Italian
- Signing the informed consent form
Criteria the registry did not label
- Group A
Age in the registry: 30 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Irccs Aoubo Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.